
    
      This is a phase 3 study.

      Primary Objective:

      â€¢ To evaluate clinical outcomes in patients with suspected or confirmed COVID-19 with early
      moderate to severe disease in a randomized controlled trial.

      Secondary Objectives:

        -  To evaluate quantitative viral load over time

        -  To evaluate length of hospital stay and days in ICU

        -  To evaluate toxicity of the treatment options

        -  To evaluate rate of readmission after hospital discharge

        -  To evaluate duration of clinical symptoms

      Arm A:

      Control Arm - Supportive Care Only

      Arm B:

      Hydroxychloroquine 400 mg po bid on Day 1 Hydroxychloroquine 200 mg po bid Days 2 through 5

      Arm C:

      Hydroxychloroquine as in Arm B AND Azithromycin 500 mg po on Day 1 Azithromycin 250 mg po
      days 2 through 5
    
  